Further to our December 12, 2013 post, on January 14, 2014, Chief ALJ Charles E. Bullock issued Order No. 4 in Certain Antivenom Compositions and Products Containing the Same (Inv. No. 337-TA-903).

By way of background, the investigation is based on an October 20, 2013 complaint filed by BTG International Inc. of West Conshohocken, Pennsylvania alleging violations of Section 337 in the importation into the U.S. and sale of certain antivenom compositions and products containing the same that infringe one or more claims of U.S. Patent No. 8,048,414. See our November 1, 2013 post for more details on the complaint. According to the Notice of Investigation, the Commission has identified Veteria Laboratories of Mexico; BioVeteria Life Sciences of Prescott, Arizona; Instituto Bioclon S.A. de C.V. of Mexico; Laboratories Silanes SA de CV of Mexico; The Silanes Group of Mexico; and Rare Disease Therapeutics, Inc. of Franklin, Tennessee as the respondents in this investigation. See our December 2, 2013 post for more details on the Notice of Investigation.

In the Order, ALJ Bullock set April 10, 2015 as the target date for completing the investigation (which is approximately sixteen months after institution of the investigation). In addition, ALJ Bullock directed the parties to submit proposed procedural schedules by January 17, 2014. ALJ Bullock further noted that the Markman hearing will take place on April 10, 2014 and the evidentiary hearing in this investigation will commence on August 11, 2014, for purposes of preparing proposed procedural schedules.